FDA accelerated approval for talquetamab-tgvs in multiple myelomaNov 12Regulatory decisionJohnson & Johnsontalquetamab
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
SunRISe-1 bladder cancer trial posts Phase 2b results; TiTan myeloma trial registeredJul 31Weekly roundup, 2 itemsdaratumumabJohnson & Johnson
Montefiore registers Phase 1 trial pairing Talquetamab with belantamab mafodotin in myelomaJul 22Trial updatebelantamabbelantamab mafodotin
J&J raises 2026 sales and EPS guidance after strong Q2 resultsJul 15Quarterly updateJohnson & Johnson